Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

Anastasios Kyriazoglou; Konstantinos Koutsoukos; Flora Zagouri; Michalis Liontos; Efthimios Dimitriadis; Dina Tiniakos; Meletios Athanasios Dimopoulos

doi:10.2147/TCRM.S220804

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

Ther Clin Risk Manag. 2020 Feb 27:16:141-146. doi: 10.2147/TCRM.S220804. eCollection 2020.

Authors

Anastasios Kyriazoglou¹, Konstantinos Koutsoukos¹, Flora Zagouri¹, Michalis Liontos¹, Efthimios Dimitriadis², Dina Tiniakos^{3

4}, Meletios Athanasios Dimopoulos¹

Affiliations

¹ Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece.
² Department of Genetics, Agios Savvas Hospital, Athens, Greece.
³ Department of Pathology Aretaion Hospital, National & Kapodistrian University of Athens, Athens, Greece.
⁴ Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.

Abstract

Epithelioid hemangioendothelioma (EHE) is a rare vascular malignant tumor with indolent course. Liver transplantation for local disease is the treatment of choice. In the metastatic setting there is no consensus regarding the appropriate systemic treatment. We present two cases of metastatic hepatic epithelioid hemangioendothelioma (hEHE) treated with the combination of Doxorubicin and Olaratumab. Both patients showed Stable Disease (SD) as a response, after the completion of six cycles of this combination therapy.

Keywords: 1st line treatment; Olaratumab and Doxorubicin; metastatic hepatic epithelioid hemangioendothelioma.

Publication types

Case Reports